Monthly cyclic therapy in heavily pretreated HIV-infected patients

AIDS Patient Care and STDs

Volumn 15, Issue 4, 2001, Pages 177-179

  Soriano, Vincent L ^a   Barreiro, Pablo ^a   De Mendoza, Carmen ^a   Dona, Carmen ^a   González Lahoz, Juan ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE;

CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PATIENT COMPLIANCE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; HIV; HIV INFECTIONS; HUMANS;

EID: 0035040361     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/10872910151133666     Document Type: Letter

References (6)

1. Introduction of drug resistance testing in clinical practice
2. Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens
3. Multiple concurrent reverse transcriptase and protease mutations and multidrug-resistance of HIV-1 isolates from heavily treated patients
4. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
5. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype